Persistence. It cannot be excluded that loperamide is persistent, due to the lack of data.
Bioaccumulation. It cannot be excluded that loperamide bioaccumulates, due to the lack of data.
Toxicity. It cannot be excluded that loperamide is toxic, due to the lack of data.
Risk. The use of loperamide has been considered to result in low risk of environmental impact (2016).
Environmental information is missing on fass.se for loperamide (2023-01-23). It is voluntary for manufacturers to provide information on environmental impact on fass.se. Risk comes from the Report Goodpoint 2016.
Pharmaceuticals residues in the aquatic environment in Sweden
Loperamide has been found in drinking water and treated wastewater in Region Stockholm, Sweden, in 2019. Loperamide has been included in the measurement program in Region Stockholm in recent years but was below the quantification limit. Loperamide has been included in national screening programs (2010 and 2014 respectively).
Report Goodpoint 2016
The levels in fish are not relevant comparing to human plasma levels as it is a locally acting medicine. Effect studies are missing. Loperamide can be excluded from monitoring programs in Region Stockholm due to low risk.
- Provtagningar av läkemedelsrester i vatten, sediment och fisk för Region Stockholm.
- IVL Swedish Environmental Research Institute Ltd. Fick J, Lindberg RH, Kaj L, Brorström-Lundén E. Results from the Swedish National Screening Programme 2010. Subreport 3, B 2014 Pharmaceuticals.
- IVL Swedish Environmental Research Institute Ltd Fick J, Lindberg RH, Fång J, Magnér J, Kaj L, Brorström-Lundén E. Screening 2014. Analysis of pharmaceuticals and hormones in samples from WWTPs and receiving waters. Rapport C 135.
- Goodpoint. Prioritering av läkemedel med miljörisk inom SLL. Stockholm: Goodpoint; 2016. Rapport LS 2016–0634.
Author: Health and Medical Care Administration, Region Stockholm